(Q38003074)

26 August 2017

Translation of molecular pathways into clinical trials of neuroendocrine tumors (English)

1 reference

26 August 2017

Marianne Pavel

1

1 reference

26 August 2017

11 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

97

1 reference

26 August 2017

1

1 reference

26 August 2017

99-112

1 reference

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

26 August 2017

1 reference

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors

21 January 2018

1 reference

VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis

21 January 2018

1 reference

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)

21 January 2018

1 reference

Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes

21 January 2018

1 reference

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

21 January 2018

1 reference

Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies

21 January 2018

1 reference

Molecular pharmacology of somatostatin receptor subtypes

21 January 2018

1 reference

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways

21 January 2018

1 reference

Antitumor effects of somatostatin

21 January 2018

1 reference

Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours

21 January 2018

1 reference

Pasireotide (SOM230): development, mechanism of action and potential applications

21 January 2018

1 reference

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.

21 January 2018

1 reference

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies

21 January 2018

1 reference

The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.

21 January 2018

1 reference

Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors.

21 January 2018

1 reference

Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines

21 January 2018

1 reference

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

Interferon in the management of neuroendocrine GEP-tumors: a review

21 January 2018

1 reference

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

21 January 2018

1 reference

Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

21 January 2018

1 reference

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors

21 January 2018

1 reference

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

21 January 2018

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

21 January 2018

1 reference

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy

21 January 2018

1 reference

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

21 January 2018

1 reference

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

21 January 2018

1 reference

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

Glycemic control in patients with insulinoma treated with everolimus

21 January 2018

1 reference

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.

21 January 2018

1 reference

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

21 January 2018

1 reference

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

21 January 2018

1 reference

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

21 January 2018

1 reference

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

21 January 2018

1 reference

Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas.

21 January 2018

1 reference

Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?

21 January 2018

1 reference

Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours

21 January 2018

1 reference

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting

21 January 2018

1 reference

MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype

21 January 2018

1 reference

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

Small molecule inhibitors of STAT3 for cancer therapy

21 January 2018

1 reference

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

Angiopoietin-2 promotes disease progression of neuroendocrine tumors

21 January 2018

1 reference

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

21 January 2018

1 reference

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

21 January 2018

1 reference

SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000336089

1 reference

26 August 2017

1 reference

PubMed ID

22508344